Medicine and Dentistry
Hepatocellular Carcinoma
98%
Immune Checkpoint Inhibitor
98%
Hepatitis C Virus
73%
Adverse Event
54%
Liver Cirrhosis
50%
Cancer Treatment
46%
Polyp
42%
Hepatitis B Virus
42%
Adenoma
41%
Diseases
40%
Malignant Neoplasm
39%
Chronic Liver Disease
37%
Alcohol Liver Disease
36%
Immunity
34%
Toxic Hepatitis
34%
Surgery
33%
Neoplasm
29%
Alcohol-Related Liver Disease
28%
Liver Toxicity
28%
Bile Duct
28%
Observational Study
27%
Colon
27%
Liver Injury
27%
Colon Polyp
25%
Hepatitis Virus
24%
Endoscopic Mucosal Resection
23%
Language Processing
23%
Hepatitis B
23%
Cross Sectional Study
23%
Quality of Life
23%
Arterial Embolization
23%
Platelet
23%
Thrombocytopenia
23%
Veterans Affairs
23%
Argon Plasma Coagulation
23%
Gallbladder
23%
Cohort Effect
23%
Recurrence Risk
23%
Diarrhea
23%
Common Hepatic Duct
23%
Pancreas Adenocarcinoma
23%
Immunotherapy
23%
Hepacivirus
23%
Telaprevir
23%
Colitis
23%
Hepatitis C
23%
Hypersplenism
23%
Hepatology
23%
Prospective Cohort Study
23%
Diagnosis
23%
Keyphrases
Immune Checkpoint Inhibitors
100%
Cancer Patients
55%
Hepatocellular Carcinoma
52%
Hepatitis C Virus
46%
Adverse Events
34%
Drug-induced Liver Injury
34%
Clinical Characteristics
31%
Histopathological Features
30%
Liver
28%
Colon
27%
Alcoholic Liver Disease
25%
Viral Hepatitis
24%
Neglected Population
23%
Platelet Count
23%
Partial Splenic Artery Embolization
23%
United States
23%
Diarrhea
23%
Natural Language Processing
23%
Prospective Observational Study
23%
Pancreatic Adverse Events
23%
Hispanic Patients
23%
Anticancer Therapy
23%
Thrombocytopenia
23%
Adenoma Recurrence
23%
Flat Lesions
23%
Pancreatic Ductal Adenocarcinoma
23%
Argon Plasma Coagulation
23%
Colon Polyps
23%
Immunosuppressive Therapy
23%
Endoscopic mucosal Resection
23%
Center Experience
23%
Recurrence Rate
23%
Immune-mediated Liver Injury
23%
Distinctive Features
23%
Patients with Cancer
23%
Adverse Impact
23%
Hepatobiliary Toxicity
23%
Colitis
23%
Prognostic Value
23%
Drug Development
23%
Endoscopic Features
23%
Retinal Activity
23%
Liver Disease Diagnosis
23%
Older Adults
23%
Bile Duct
23%
Hepatitis C Virus Infection
23%
Quality of Life
23%
Hepatology
23%
Sofosbuvir
23%
MD Anderson Cancer Center
23%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
92%
Malignant Neoplasm
74%
Hepatitis C Virus
69%
Liver Cell Carcinoma
50%
Liver Disease
34%
Neoplasm
29%
Ethanol
28%
Solid Malignant Neoplasm
28%
Hepatitis B Virus
25%
Hepatitis B
25%
Hepatitis C
25%
Liver Injury
25%
Recurrent Disease
25%
Observational Study
24%
Virus Hepatitis
24%
Hepatotoxicity
23%
Pancreas Adenocarcinoma
23%
Drug Development
23%
Recurrence Risk
23%
Diseases
23%
Prospective Cohort Study
23%
Hepacivirus
23%
Adenoma
23%
Sofosbuvir
23%
Cross-Sectional Study
23%
Alcohol Liver Disease
23%
Adverse Event
17%
Overall Survival
13%
Toxic Hepatitis
11%
Polyp
11%
Combination Therapy
10%
Alanine Aminotransferase
9%
Chronic Liver Disease
9%
Retrospective Study
8%
Remission
8%
Clinical Feature
8%
Clinical Trial
7%
Hematologic Malignancy
7%
Hepatitis B Antigen
7%
Hepatitis B Core Antibody
7%
Prevalence
7%
Nonhodgkin Lymphoma
6%
Colon Polyp
5%
CYP3A
5%
Nonalcoholic Fatty Liver
5%
Chronic Hepatitis C
5%